MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamanetworkopen.2021.0313

Медицинская библиотека · JAMA network open · 2021

Association of Anti-Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease.

Cohen-Mekelburg Shirley, Wallace Beth I, Van Tony, Wiitala Wyndy L, Govani Shail M, Burns Jennifer, Lipson Rachel, Yun Huifeng, Hou Jason, Lewis James D, Dominitz Jason A, Waljee Akbar K

СтатьяПоддержка NIH: внешняя программаПоддержка правительства СШАПеревод пока не подготовлен

Аннотация

IMPORTANCE

Inflammatory bowel disease (IBD) is commonly treated with corticosteroids and anti-tumor necrosis factor (TNF) drugs; however, medications have well-described adverse effects. Prior work suggests that anti-TNF therapy may reduce all-cause mortality compared with prolonged corticosteroid use among Medicare and Medicaid beneficiaries with IBD.

OBJECTIVE

To examine the association between use of anti-TNF or corticosteroids and all-cause mortality in a national cohort of veterans with IBD.

DESIGN, SETTING, AND

PARTICIPANTS

This cohort study used a well-established Veteran's Health Administration cohort of 2997 patients with IBD treated with prolonged corticosteroids (≥3000-mg prednisone equivalent and/or ≥600 mg of budesonide within a 12-month period) and/or new anti-TNF therapy from January 1, 2006, to October 1, 2015. Data were analyzed between July 1, 2019, and December 31, 2020.

EXPOSURES: Use of corticosteroids or anti-TNF.

MAIN OUTCOMES AND MEASURES: The primary end point was all-cause mortality as defined by the Veterans Health Administration vital status file. Marginal structural modeling was used to compare associations between anti-TNF therapy or corticosteroid use and all-cause mortality.

RESULTS

A total of 2997 patients (2725 men [90.9%]; mean [SD] age, 50.0 [17.4] years) were included in the final analysis, 1734 (57.9%) with Crohn disease (CD) and 1263 (42.1%) with ulcerative colitis (UC). All-cause mortality was 8.5% (n = 256) over a mean (SD) of 3.9 (2.3) years' follow-up. At cohort entry, 1836 patients were new anti-TNF therapy users, and 1161 were prolonged corticosteroid users. Anti-TNF therapy use was associated with a lower likelihood of mortality for CD (odds ratio [OR], 0.54; 95% CI, 0.31-0.93) but not for UC (OR, 0.33; 95% CI, 0.10-1.10). In a sensitivity analysis adjusting prolonged corticosteroid users to include patients receiving corticosteroids within 90 to 270 days after initiation of anti-TNF therapy, the OR for UC was statistically significant, at 0.33 (95% CI, 0.13-0.84), and the OR for CD was 0.55 (95% CI, 0.33-0.92).

CONCLUSIONS AND RELEVANCE: This study suggests that anti-TNF therapy may be associated with reduced mortality compared with long-term corticosteroid use among veterans with CD, and potentially among those with UC.

Для цитирования: Cohen-Mekelburg Shirley, Wallace Beth I, Van Tony, Wiitala Wyndy L, Govani Shail M, Burns Jennifer, Lipson Rachel, Yun Huifeng, Hou Jason, Lewis James D, Dominitz Jason A, Waljee Akbar K. Association of Anti-Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease.. JAMA network open. 2021. DOI: 10.1001/jamanetworkopen.2021.0313.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.